Oxford-AstraZeneca coronavirus vaccine triggers immune response among adults - CNBC

LONDON — British pharmaceutical giant AstraZeneca on Monday said its potential Covid-19 vaccine had produced a similar immune response in both older and younger adults.

AstraZeneca, which is developing its potential Covid-19 vaccine in collaboration with the University of Oxford, said adverse responses to the vaccine among the elderly were also found to be lower.

"It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher," an AstraZeneca spokesman told CNBC via email.

The vaccine being developed by the University of Oxford and AstraZeneca is thought to be one of the frontrunners to secure regulatory approval.